A phase 2 study of A fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in A 3-times-daily regimen to treat patients with recurrent metastatic breast cancer

Cancer

Volumn 116, Issue 6, 2010, Pages 1440-1445

  Hortobagyi, Gabriel N ^a   Heim, William ^b   Hutchins, Laura ^c   Rivera, Edgardo ^d   Mason, Bernard ^e   Booser, Daniel J ^a   Kirshner, Jeffrey ^f  

^a UNIVERSITY OF TEXAS   (United States)

^b Hematology and Oncology Associates of Northeastern PA   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e Pennsylvania Oncology Hematology Associates   (United States)

^f Hematology Oncology Associates of Central New York   (United States)

Author keywords

Breast cancer; Leucovorin; Metastatic; Uracil and ftorafur (UFT)

Indexed keywords

ANTHRACYCLINE; FOLINIC ACID; TAXANE DERIVATIVE; UFT;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CHOREOATHETOSIS; CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTESTINE OBSTRUCTION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SKIN METASTASIS; STOMATITIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUCOVORIN; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; RETREATMENT; TEGAFUR; URACIL;

EID: 77949351429     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24900     Document Type: Article

References (16)

1. Physician's Desk Reference. 52nd ed. New York: Thomson Healthcare; 1998: 2463-2464.
2. Rougier P, Buyse M, Ryan L, et al. Meta-analysis of all studies comparing intravenous bolus administration to continuous infusion of 5-fluorouracil in patients with advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol. 1997;16:267a. Abstract 946.
3. Schilsky RL. Antimetabolites. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore, Md: Williams and Wilkins; 1992: 301-317.
4. Fata F, Ron IG, Kemeny N, O'Reilly E, Klimstra D, Kelsen DP. 5-Fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer. 1999;86:1129-1134.
5. Taguchi T. Experience with UFT in Japan. Oncology. 1997;11(suppl 10):S30-S34.
6. Maehara Y, Kakeji Y, Ohno S, Baba H, Sugimachi K. Scientific basis for the combination of tegafur with uracil. Oncology. 1997;11(suppl 10):S14-S21.
7. Pazdur R, Lassere Y, Rhodes V, et al. Phase II study of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol. 1994;12:2296-2300.
8. Saltz LB, Leichman CG, Young CW, et al. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. Cancer. 1995;75:782-785.
9. Gonzalez-Baron M, Feliu J, de la Gandara I, et al. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer. 1995;31A:2215-2219.
10. Abad A, Navarro M, Sastre J, et al. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Oncology. 1997;11(suppl 10):S53-S57.
11. Feliu J, Gonzalez-Baron M, Espinosa E, et al. Uracil and tegafur modulated with leucovorin. Cancer. 1997;79:1884-1889.
12. Ron IG, Lotan A, Inbar MJ, Chaitchik S. Advanced colorectal carcinoma: redefining the role of oral tegafur. Anticancer Drugs. 1996;7:649-654.
13. Skillings JR. 5-FU or UFT combine with leucovorin for previously untreated metastatic colorectal cancer. Oncology. 1997;11(suppl 10):S48-S49.
14. Carmichael J. UFT plus leucovorin versus 5-FU plus leucovorin for metastatic colorectal cancer. Oncology. 1997;11(suppl 10):S50-S52.
15. Mamounas E, Wieand HS, Jones J, Wickerham DL, Wolmark N. Future directions in the adjuvant treatment of colon cancer. Oncology. 1997;11(suppl 10):S44-S47.
16. Sole LA, Albanell J, Bellmunt J, Ribas A, Gallego O, Carulla J. Phase II study of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. Cancer. 1995;75:831-835.